Effect of NMN Supplementation on Organ System Biology
VAN
Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology
1 other identifier
interventional
56
1 country
1
Brief Summary
The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2020
CompletedFirst Posted
Study publicly available on registry
September 30, 2020
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 4, 2025
CompletedResults Posted
Study results publicly available
March 11, 2026
CompletedMarch 11, 2026
March 1, 2026
4.4 years
September 24, 2020
January 6, 2026
March 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Muscle Insulin Sensitivity
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.
After at least 16 weeks of treatment
Secondary Outcomes (1)
Changes in Glucose Tolerance
After at least 16 weeks of treatment
Study Arms (2)
Placebo
PLACEBO COMPARATORAt least 16 weeks of placebo.
NMN supplementation
EXPERIMENTALAt least 16 weeks of NMN.
Interventions
Eligibility Criteria
You may qualify if:
- BMI 25.0-50.0 kg/m²
- Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.
You may not qualify if:
- Women who are still having menses
- Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
- Persons who consume moderate-large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
- Unstable weight (\>3% change during the last 2 months before entering the study)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Washington University School of Medicine
St Louis, Missouri, 63110, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Sarah Farabi
- Organization
- Washington University in St. Louis
Study Officials
- PRINCIPAL INVESTIGATOR
Samuel Klein, MD
Washington University School of Medicine
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2020
First Posted
September 30, 2020
Study Start
October 1, 2020
Primary Completion
March 4, 2025
Study Completion
March 4, 2025
Last Updated
March 11, 2026
Results First Posted
March 11, 2026
Record last verified: 2026-03